Clinical Trial Update: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS [Phase 2, Phase 3]

View source ↗

Summary

An update on a study of Baricitinib (LY3009104) in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome (NNS)/Chronic Atypical Neutrophilic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aicardi Goutieres Syndrome
• Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature
• Nakajo-nishimura Syndrome
• Sting-associated Vasculopathy with Onset in Infancy

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-12-21